Instances of genetic diseases to remain rampant throughout the forecast period

The rare disease treatment market covers a detailed segmentation in which the genetic diseases segment is poised to grow at a moderate pace and stay a dominant segment by therapeutic area. Almost 80 percent diseases are of genetic origin.

The genetic segment is poised to reflect a significant US$ 56 B n market valuation by the end of 2025, as per the market forecasts gathered in this research report.

Multiple aspects contribute to the growth of the rare disease treatment market

Multiple aspects contribute to the growth of the rare disease treatment market

According to our research report on the rare disease treatment market, the global market is poised to reflect a market valuation of US$ 198,487 M n in 2025 and exhibit a CAGR of 8.6% during the period of forecast.

There are various factors that are responsible for the growth of the rare disease treatment market and are analysed in this research report along with their impact few years down the line.

The global rare disease treatment market such as increasing government assistance, provision of incentives to pharmaceutical companies, increasing awareness among people, the physician to physician communication to find efficient treatment methods to treat rare diseases, increase in facilities for patients affected by rare diseases, rise in the incentives for research owing to the prevalence of non-profit organizations that promote health to treat rare diseases, other government incentives and regulations such as reduced tax on pricy medicines, higher funding on the research on diseases and their treatments, promising regulatory assistance along with the advantage of monopolistic market etc., which contribute to the growth of the global rare disease treatment market.

The few other factors that pull the growth of the global market, such as the challenges in the research and development, delay in diagnosis thereby delaying the treatment, limitations with respect to expertise, characteristic lack of attractiveness from an economic standpoint, which eventually has resulted in the scarce commercial interest for private investors, lack of regulatory framework in developing economies coupled with lack of skilled healthcare personnel.

Every year, number of lives is losing because of the spread of infections in hospitals and clinics and other healthcare settings. The growth of the market can be attributed to the factors such as the increasing demand of sterilization and disinfection products by pharmaceutical companies, hospitals and medical device manufacturers; increasing incidence of hospital acquired infections; increasing focus on food sterilization and disinfection and rising number of surgical procedures and rising geriatric population and prevalence of chronic diseases.

Many new contagious diseases arising have been identified in last three decades, such as AIDS, Ebola and Hantavirus are some of the major diseases. Geographically, North America is expected to be one of the largest markets and dominate the market growth for infections control.

The growth of the market can be attributed to the factors such as the increasing demand of sterilization and disinfection products by pharmaceutical companies, hospitals and medical device manufacturers, increasing incidence of hospital acquired infections; increasing focus on food sterilization and disinfection and rising number of surgical procedures and rising geriatric population and prevalence of chronic diseases. These steps are the part of infection control procedures. Proper hand washing is the most effective way to prevent the spread of infections in hospitals.
New diseases are constantly appearing, which are susceptible to, protect against infectious diseases due to constant changes in human lifestyles and environments.

As treatment options are limited, focus on NiV management should be on prevention. Preventive strategies include interventions to prevent farm animals from acquiring NiV by eating fruit contaminated by bats. Farms should be designed to reduce overcrowding to avoid rapid spread of disease between animals and should not be near fruit trees that attract bats.

Consumption of contaminated sap should be avoided. However, other, more acceptable methods would include physical barriers to prevent bats from accessing and contaminating sap.

A number of vaccine candidates have been found to be capable of complete protection against NiV disease in preclinical studies of small animal and nonhuman primate models.

While WHO has declared NiV to be a priority pathogen, pharmaceutical companies may be reluctant to fund trials in underdeveloped countries that can ill afford medications or vaccines. Fortunately, a new international coalition of governments and pharmaceutical companies called the Coalition for Epidemic Preparedness Innovations (CEPI) was formed in January 2017 to develop safe, effective, and affordable vaccines for diseases with pandemic potential, such as NiV.

Hospital acquired infections (HAIs) are one of the leading cause of death across the globe. They are also referred to as nosocomial infections or Healthcare-associated Infections. According to Centers for Disease Control and Prevention (CDC), 1 out of every 25 hospital admitted patient gets contracted with HAIs. The global hospital acquired therapeutics market has observed a significant growth owing to rising number of hospital admitted patients and improved diagnostics capable of differentiating different strains of microbes. Complacency among healthcare providers and poor maintenance of hygiene are the two major preventable causes leading to HAIs. The global market is facing significant challenges such as growing antimicrobial resistance among certain strains of bacteria eg. Methicillin-Resistant Staphylococcus Aureus (MRSA). The major drivers of global hospital infection therapeutics market are the rising number of hospital admitted patients, poor infrastructure, understaffing and insufficient hospital equipment, overcrowding and lack of knowledge about blood transfusion safety measures, and rising geriatric population. However, stringent regulatory requirement, high cost of treatment and lack of transparent reimbursement scenario, are likely to hinder the market growth.

On the basis of drug type, the market is segmented into Antibiotics Drugs, Antifungal Drugs, Antiviral Drugs and Others. According to application, the global market is segmented into, Bloodstream Infections, Pneumonia, Surgical Site Infections, Urinary Tract Infections, Gastrointestinal Disorders and Other Hospital Infections. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific and LAMEA. New drug approval and acquisitions are key strategies adopted by the top industry players. For instance, FDA approved a new drug named Oritavancin, an intravenous antibiotic, for the treatment of drug-resistant bacteria, including MRSA. Merck & Co. has acquired Cubist Pharmaceuticals, a company with late-stage pipeline focusing on healthcare-acquired bacterial infections. The companies profiled in the report include, Sanofi S.A., GlaxoSmithKline plc, AstraZeneca plc, Merck & Co., Inc., Pfizer, Inc, Actavis plc, Bayer AG, Johnson & Johnson, Bristol-Myers Squibb Company and Cubist Pharmaceuticals, Inc.